Parikshit Somani's Four-Year Ban and the Limits of the Trimetazidine Contamination Defence

The Astana court had no big stands. It belonged to the lower tier of professional tennis, where the scoreboard sometimes shows only the score and not the serve speed, where every player carries his own tape to court and finds a partner on the morning of the draw. Parikshit Somani was there.

Born in 2026, Indian, a doubles specialist. His career-high ranking is No. 256 in doubles — a number only people who actually follow the Challenger circuit understand. No television. Những nhịp đập không ai nghe thấy.

Then his urine sample was sealed, shipped, and came back carrying the name of a substance: trimetazidine.

On Wednesday, the International Tennis Integrity Agency — the ITIA — announced that an independent tribunal had banned Somani for four years, until September 2029. He is 26. When the ban ends, he will be 31. For the duration, he cannot play, cannot coach, and cannot attend any event organised by World Tennis, the WTA, the ATP, the Grand Slams, or any national federation.

I have stood at courts on the same tier as Astana. Not that one, but the same tier. And there is one thing I know about that tier: it was not built to protect anyone.

It is worth being precise about the substance first, because its name sounds like an ordinary cold medicine.

Trimetazidine treats angina. Its mechanism is metabolic: it helps muscle cells produce energy more efficiently under oxygen shortage, by shifting fuel preference from fatty-acid oxidation toward glucose oxidation. For a doubles player on the lower tier, where a week can mean four or five three-set matches on hard courts, saving energy at the cellular level is a very concrete advantage.

That mechanism is why WADA placed trimetazidine on the Prohibited List in 2026, under category S4 — hormones and metabolic modulators. Before that, it had already surfaced in debates about endurance performance across several sports.

Trimetazidine is not unfamiliar to tennis. It is the substance that put Kamila Valieva, the Russian figure skater, at the centre of the storm at the Beijing 2026 Olympics. Valieva was later banned for four years by the Court of Arbitration for Sport, retroactive to December 25, 2026. It is also the substance in the case of Sun Yang, the Chinese swimmer, in 2026, when he received a three-month ban.

Three sports. Three legal systems. Three defences. One substance.

And in all three cases, the notable thing was never the substance. It was the explanation.

Somani told the ITIA that his positive test came from contaminated food. A family member was taking medication, and the medicine got into what he ate.

The structure of that explanation matches almost exactly the one Valieva's lawyers put forward: contamination from food prepared by a relative who was taking a prohibited substance. Two athletes, two sports, two continents, one script.

At a hearing in August, Somani's defence did not prove the source of the alleged contamination. The tribunal concluded that the food-contamination theories were “scientifically implausible,” “highly speculative,” and “unconvincing.”

Those three adjectives deserve a pause. They do not say Somani lied. They say his story could not stand up to science.

This is the part most short reports skip: inside the anti-doping system, a contamination source that cannot be proven is treated as though it does not exist. The burden of proof sits with the athlete, not with the investigator.

I have spent years standing at the edge of courts, recording the things that never reach a scoreboard. There is a pattern I recognised late: the anti-doping system operates more like a probability filter than a criminal court. It does not ask “are you guilty.” It asks “can you prove you are innocent.” Those two questions do not use the same standard, and the gap between them is where careers disappear.

To understand why the food-contamination defence almost always fails, you have to see its structure.

A scientifically valid contamination defence has to answer a chain of questions: which medicine contained the substance; whose medicine it was; at what dose and for how long it was taken; where it was stored; how the food was prepared; what metabolite concentration remained in the sample; and whether that concentration matches the described route of exposure. Every link in that chain is an experiment, a medical record, a statement open to independent verification.

For a player on the lower tier, that chain is practically impossible. You do not have your own laboratory. You do not have a sports lawyer specialising in doping with you from day one. You do not have a communications team reconstructing a timeline from data. You have a relative, a kitchen, and a urine sample.

Trimetazidine makes that harder. The substance is excreted mainly unchanged in urine, with a short half-life of only a few hours. It can be detected at very low concentrations, and it disappears very quickly. For an athlete trying to prove contamination, the window to reconstruct events is extremely narrow; for an anti-doping body, a low detection threshold is an advantage.

That is why I do not read the Somani case purely as a story about cheating. I read it as a story about asymmetry.

Compare it with the Valieva case. At Beijing 2026, the story was not that she tested positive. It was the timing of how information was handled, the gap between the December 2026 sample and the moment the result became public, the sight of a 15-year-old skating while the whole world already knew. Same substance. Same four-year length. Same type of defence.

The only real difference between the two cases is how much light was shone on them. Valieva had a media apparatus, a national federation, a legal machine and a global debate about the age of athletes. Somani had an ITIA press release.

Có một ngọn lửa trong phòng thay đồ. But not every locker room has someone who stays behind to look.

The ITIA was created to separate tennis's anti-doping and anti-corruption work from the tournaments themselves — an independent governance model many sports still lack. In principle, that is progress. The agency is not a tournament organiser and holds no direct interest in whether a famous player is suspended. But independence only solves the conflict-of-interest problem. It does not solve the resource asymmetry between athletes.

Now to the part rarely discussed: the competition system Somani belonged to.

Professional tennis is not one system. It is several systems stacked on top of each other, and the bottom layer runs on a completely different logic. For the top hundred players, every tournament week is an economic operation: medical staff, nutritionists, physiotherapists, data analysts, communications staff. On Somani's tier, that operation is close to zero. Players book their own tickets, find their own lodging, manage their own food in a city whose language they may not speak.

Somani is a doubles specialist. That is not a small detail. Doubles has fewer tournaments, less prize money, fewer viewers, and it is often home to players who lack the weapons to play singles at the highest level. It is also where players must play more matches in less time. A doubles set lasts less than a singles set on average, but the number of matches per week can double.

I once sat in a hotel corridor at a Challenger and heard a 24-year-old say he ate the same dish for seven straight days, because it was the only thing whose ingredients he could be certain about. He did not say it as a complaint. He said it the way you describe a work procedure.

That is why the food-contamination defence is both easy to believe and impossible to prove. On that tier, food genuinely is an uncontrolled variable. But precisely because it is uncontrolled, it can never function as evidence.

At Challenger and ITF level, testing frequency is far lower than at the majors, yet every sample is processed under the same rulebook. That creates a familiar paradox: the players tested least are the ones least equipped to defend themselves when a test comes back positive.

The anti-doping system cannot distinguish between a truthful person in an unverifiable situation and a person constructing an unverifiable story. When it cannot distinguish, it chooses the option that favours deterrence, not individual fairness.

This is where I want to break from the conventional reading. The conventional reading says: Somani copied Valieva, got caught out, and that is the end of it. That reading is convenient, but it ignores a detail in the history of this substance.

Trimetazidine has one of the densest contamination records in sport. It appears in common cardiac medications in many countries, including Russia and Kazakhstan, the two countries tied to the cases above. It is widely sold, requires no complicated prescription process in many places, and exists under many brand names. Positive cases involving this substance are high not only because many people use it, but because it slips into the body unintentionally very easily.

In other words, the food-contamination defence in trimetazidine cases is not a strategy invented for convenience. It is a structural consequence of the substance itself. When a substance is both widespread in public medicine and detectable at low thresholds, contamination defences will naturally be common.

That is why the fact that Valieva and Somani offered near-identical explanations does not necessarily prove the second is a copy of the first. It may only prove that both were facing the same type of substance, and the same gap in the system of proof.

But here I have to turn the other way, because an article that only sides with the athlete is as partial as one that only sides with the investigator.

Read the tribunal's three adjectives carefully: scientifically implausible, highly speculative, unconvincing. This is not the language of a court convicting. It is the language of a panel rejecting an argument because it is not tight enough. And in doping, an argument that is not tight enough has real consequences: if the panel accepted it, every future positive athlete could invoke a family member on cardiac medication. At that point, the system would have nothing left to stand on.

That leads to a paradox few in the industry want to state: the anti-doping system protects the integrity of sport by accepting that some innocent people will be sanctioned. This is not an operational error. It is a design parameter.

On the lower tier, that parameter costs far more.

How much does a No. 256 doubles player earn from tennis? On that tier, a tournament's prize money can be less than the cost of travel, lodging and hiring a partner. Many players at that level live on family money, small local club sponsorship, or coaching income. A four-year ban is not only four years without competition. It is four years without coaching inside the system, without being present at a court, without maintaining professional relationships.

At 26, that is the entire good part of a career.

Valieva was banned for four years and remains a name invoked in debates about sport and youth. Somani was banned for four years and will cease to be a name.

There is one legal detail in the ITIA announcement I consider more important than the sentence itself.

The ban does not only stop Somani from competing. It stops him from coaching, and from attending any event within the professional tennis system or national federations.

Think about what that means for the career of a No. 256 doubles player. The most common survival route after a playing career ends is a move into coaching, into academies, into clubs. For a lower-tier player, that is often the only plan B. The ban takes away plan B too.

From years of following teams and players, I have learned that the real punishment is never in the number of years. It is in how many doors close at the same time. Four years without competing is a sporting sanction. Four years without being present is a professional sanction. Together, they come close to an identity sanction.

Tôi nhìn, tôi ghi, tôi giữ.

So what does this case leave behind?

Technically, it confirms a rule that has been clear for more than a decade: a food-contamination defence, if not supported by quantitative data, will almost certainly fail. Somani is not the first case, and under the current structure he will not be the last.

Systemically, it exposes a gap nobody has filled. Between athlete and anti-doping body lies a zone neither side controls: the zone of the family meal, the kitchen, the pills that appear in no record anywhere. Nobody wants to regulate that zone, because regulating it means admitting that part of the responsibility for contamination does not belong to the athlete.

Humanly, it leaves a 26-year-old Indian player, career-high doubles ranking 256, walking out of the system at 31 with no match left to look back on.

Trái bóng lăn qua, người ở lại.

In the coming weeks I will watch two things. One is whether Somani appeals to the Court of Arbitration for Sport, and if so, whether a new defence team can supply the quantitative chain the August hearing lacked. The other is how the ITIA handles the next trimetazidine cases on the lower tier: whether the agency adds clearer guidance on food-contamination evidence for players without legal teams, or leaves in place a standard designed for people with money.

Một nhịp, một ngày, một mùa bóng. On the lowest tier of professional tennis, the pulse stays steady. It is just that nobody stands close enough to hear it anymore.